Push for personal medicine boosts firm: Software developer RND is busy working on gene-based diagnostic devices
The future of medicine is personal. That’s been the mantra of the pharmaceutical industry for the last decade-since the human genome was sequenced for the first time. But before Eli Lilly and Co. and its peers can develop and sell drugs that treat only patients with a specific gene, it needs sophisticated devices to test if a patient has that gene. And those devices need sophisticated software to make them run. That’s where The RND Group Inc. comes in. The…